This is a phase I study investigating the toxicity and the potential efficacy of thalidomide and oral cyclophosphamide in patients with hormone refractory prostate cancer (HRPC), previously treated with docetaxel-based regimens

Thalidomide in combination with oral daily cyclophosphamide in patients with pretreated hormone refractory prostate cancer: a phase I clinical trial / Giuseppe Di, Lorenzo; Riccardo, Autorino; DE LAURENTIIS, Michelino; Valeria, Forestieri; Carmela, Romano; Antonella, Prudente; Francesco, Giugliano; Ciro, Imbimbo; Vincenzo, Mirone; DE PLACIDO, Sabino. - In: CANCER BIOLOGY & THERAPY. - ISSN 1538-4047. - STAMPA. - 6:(2007), pp. 313-317.

Thalidomide in combination with oral daily cyclophosphamide in patients with pretreated hormone refractory prostate cancer: a phase I clinical trial.

DE LAURENTIIS, MICHELINO;DE PLACIDO, SABINO
2007

Abstract

This is a phase I study investigating the toxicity and the potential efficacy of thalidomide and oral cyclophosphamide in patients with hormone refractory prostate cancer (HRPC), previously treated with docetaxel-based regimens
2007
Thalidomide in combination with oral daily cyclophosphamide in patients with pretreated hormone refractory prostate cancer: a phase I clinical trial / Giuseppe Di, Lorenzo; Riccardo, Autorino; DE LAURENTIIS, Michelino; Valeria, Forestieri; Carmela, Romano; Antonella, Prudente; Francesco, Giugliano; Ciro, Imbimbo; Vincenzo, Mirone; DE PLACIDO, Sabino. - In: CANCER BIOLOGY & THERAPY. - ISSN 1538-4047. - STAMPA. - 6:(2007), pp. 313-317.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/338076
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact